USD 0.0
(0.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2021 | 13.95 Million USD | 119.14% |
2020 | 6.36 Million USD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2022 Q2 | 4.05 Million USD | 0.97% |
2022 Q1 | 4.01 Million USD | 0.0% |
2021 FY | 13.95 Million USD | 119.14% |
2021 Q2 | 2.77 Million USD | 0.0% |
2020 FY | 6.36 Million USD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
AstraZeneca PLC | 46.91 Billion USD | 99.97% |
Bristol-Myers Squibb Company PFD CONV 2 | 45 Billion USD | 99.969% |
CSPC Pharmaceutical Group Limited | 31.45 Billion USD | 99.956% |
Novartis AG | 46.66 Billion USD | 99.97% |
PT Kalbe Farma Tbk. | 1.97 Billion USD | 99.295% |